At this ACR Convergence 2025 session, experts discussed emerging concepts with axial spondyloarthritis, including the most effective MRI specifications for diagnosis, challenges with axial juvenile spondyloarthritis & the many mimics of axSpA.
Search results for: hospital
Reflections on B Cells in SLE & Lupus Nephritis
At the Dubois Memorial Lecture presented at ACR Convergence 2025, Shaun Jackson, MD, PhD, discussed the evolving understanding of the role of B cells in SLE.
From Conceptual Seedling to Tree of Knowledge
In a panel discussion at ACR Convergence 2025, three experts provided insight into how mentorship, personal values and more helped them develop the skills and habits necessary to become a master clinician.
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Gout & Cardiometabolic Co-Morbidities
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
What’s New in Psoriatic Arthritis?
Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
FDA Approves 2 More Denosumab Biosimilars
The FDA as approved the biosimilar treatments denosumab-nxxp (Bildyos) and denosumab-nxxp (Bilprevda) for all indications of denosumab, their reference product, including osteoporosis in postmenopausal women.
The 2025 ACR Awards of Distinction
The ACR honors excellence in rheumatology. Meet the 2025 Awards of Distinction recipients, ACR Masters & Distinguished Fellows recognized at ACR Convergence 2025.
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 328
- Next Page »